Literature DB >> 25196038

Move for Change Part III: a European survey evaluating the impact of the EPDA Charter for People with Parkinson's Disease.

B R Bloem1, F Stocchi.   

Abstract

BACKGROUND AND
PURPOSE: Move for Change is an online pan-European patient survey based on the European Parkinson's Disease Association (EPDA) Charter for People with Parkinson's Disease (PD), which states that all PD patients have the right to: be referred to a doctor with a specialist interest in PD; receive an accurate diagnosis; have access to support services; receive continuous care; and take part in managing their illness.
METHODS: This part of the survey focuses on the final two elements of the Charter. It was administered online through the EPDA website and through affiliated patient associations' websites. A total of 1591 questionnaires were received and 1546 were analysed (97.2%).
RESULTS: Approximately half of the patients (53.0%) consulted a neurologist regularly (every 4-6 months). Consultations were usually arranged as part of a follow-up process (65.5%) and lasted for 15-30 min (63.2%), with 16.1% lasting <10 min and 17.9% lasting >30 min. Patients were largely satisfied with the attention they received (63.2%) but just 11.6% of patients were involved in treatment decisions, and 39.1% prepared a list of symptom changes for discussion. Two hundred caregivers also took part in the survey, and 71.4% felt included in the treatment plan by the doctor.
CONCLUSIONS: These results highlight that PD disease-management is driven by the clinician; he/she arranges consultations and makes the majority of management decisions, rather than patients being included in the process. This survey can be used to raise awareness for PD patients, encouraging greater involvement in the management of PD.
© 2014 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Entities:  

Keywords:  Charter; EPDA; European survey; Parkinson's disease; funding; quality of care; support services

Mesh:

Year:  2014        PMID: 25196038     DOI: 10.1111/ene.12544

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

1.  Barriers and facilitators of communication about off periods in Parkinson's disease: Qualitative analysis of patient, carepartner, and physician Interviews.

Authors:  Melissa J Armstrong; Tara Rastgardani; Anna R Gagliardi; Connie Marras
Journal:  PLoS One       Date:  2019-04-18       Impact factor: 3.240

2.  Improving patient-centred care for persons with Parkinson's: Qualitative interviews with care partners about their engagement in discussions of "off" periods.

Authors:  Tara Rastgardani; Melissa J Armstrong; Connie Marras; Anna R Gagliardi
Journal:  Health Expect       Date:  2019-04-12       Impact factor: 3.377

3.  Communication About OFF Periods in Parkinson's Disease: A Survey of Physicians, Patients, and Carepartners.

Authors:  Tara Rastgardani; Melissa J Armstrong; Anna R Gagliardi; Arthur Grabovsky; Connie Marras
Journal:  Front Neurol       Date:  2019-08-19       Impact factor: 4.003

4.  Rationale and design to evaluate the PRIME Parkinson care model: a prospective observational evaluation of proactive, integrated and patient-centred Parkinson care in The Netherlands (PRIME-NL).

Authors:  Jan H L Ypinga; Angelika D Van Halteren; Emily J Henderson; Bastiaan R Bloem; Agnes J Smink; Emma Tenison; Marten Munneke; Yoav Ben-Shlomo; Sirwan K L Darweesh
Journal:  BMC Neurol       Date:  2021-07-23       Impact factor: 2.474

5.  Personalized care management for persons with Parkinson's disease: A telenursing solution.

Authors:  Francesca Mancini; Angelika D van Halteren; Tania Carta; Sue Thomas; Bastiaan R Bloem; Sirwan K L Darweesh
Journal:  Clin Park Relat Disord       Date:  2020-08-19

6.  How People with Parkinson's Disease and Health Care Professionals Wish to Partner in Care Using eHealth: Co-Design Study.

Authors:  Carolina Wannheden; Åsa Revenäs
Journal:  J Med Internet Res       Date:  2020-09-21       Impact factor: 5.428

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.